Levosimendan

Chemical formula: C₁₄H₁₂N₆O  Molecular mass: 280.285 g/mol  PubChem compound: 3033825

Therapeutic indications

Levosimendan is indicated for:

Acutely decompensated chronic heart failure (ADHF)

Population group: only adults (18 years old or older)

Levosimendan is indicated for the short-term treatment of acutely decompensated chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Levosimendan is contraindicated in the following cases:

Severe hypotension, tachycardia

at least one of
Hypotension
Tachycardia

Torsades de pointes

Torsades de pointes

Severe renal impairment (creatinine clearance <30 mL/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe hepatic impairment

Hepatic failure stage IV

Mechanical obstructions of ventricles

at least one of
LVOTO - Left ventricular outflow tract obstruction
Right ventricular outflow tract obstruction

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: SIMDAX Injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈